Last A$0.04 AUD
Change Today 0.00 / 0.00%
Volume 75.1K
As of 6:57 PM 03/4/15 All times are local (Market data is delayed by at least 15 minutes).

prima biomed ltd (PRR) Snapshot

Open
A$0.04
Previous Close
A$0.04
Day High
A$0.04
Day Low
A$0.04
52 Week High
05/29/14 - A$0.06
52 Week Low
01/15/15 - A$0.03
Market Cap
48.6M
Average Volume 10 Days
5.8M
EPS TTM
A$-0.01
Shares Outstanding
1.4B
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for PRIMA BIOMED LTD (PRR)

Related News

No related news articles were found.

prima biomed ltd (PRR) Related Businessweek News

No Related Businessweek News Found

prima biomed ltd (PRR) Details

Prima BioMed Ltd. researches, develops, and commercializes medical biotechnology products in Australia. The company develops immunocellular therapeutic products for the treatment of cancer. Its lead product is CVac, an autologous dendritic cell-based product currently in clinical trials for ovarian and pancreatic cancer patients. Prima BioMed Ltd. is based in Sydney, Australia.

31 Employees
Last Reported Date: 08/27/14

prima biomed ltd (PRR) Top Compensated Officers

Chief Executive Officer, Chief Financial Offi...
Total Annual Compensation: A$250.2K
Chief Technical Officer
Total Annual Compensation: A$325.6K
General Counsel and Company Secretary
Total Annual Compensation: A$160.0K
Advisor
Total Annual Compensation: A$364.4K
Compensation as of Fiscal Year 2014.

prima biomed ltd (PRR) Key Developments

Prima Biomed Ltd. Reports Consolidated Earnings Results for the Half Year Ended December 31, 2014

Prima Biomed Ltd. reported consolidated earnings results for the half year ended December 31, 2014. For the period, the company reported loss before income tax of AUD 6,401,086 against AUD 5,920,756 for the same period a year ago. Loss attributable to owners of the company was AUD 6,401,086 or 0.51 cents per basic and diluted share against AUD 5,956,531 or 0.49 cents per basic and diluted share for the same period a year ago. Net cash flows used in operating activities were AUD 6,678,881 against AUD 8,301,296 for the same period a year ago. Payment for purchases of plant and equipment was AUD 46,848 against AUD 52,505 for the same period a year ago. During the half year ended December 31, 2014, the company incurred an operating loss after tax of AUD 6,401,086.

Stuart Roberts Appoints Stuart Roberts as Global Head of Investor Relations

Prima BioMed Ltd. announced the appointment of Stuart Roberts as Global Head of Investor Relations. Mr. Roberts is an experienced investment professional, with expertise in the healthcare and biotechnology sectors, and has been involved in Australian equity research for 16 years. He builds his reputation as one of Australia's leading sell-side biotech analysts and has been working with Baillieu Holst and Bell Potter before joining Prima.

Prima Biomed Ltd. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-12-2015

Prima Biomed Ltd. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-12-2015 . Venue: Westin St. Francis Hotel, San Francisco, California, United States.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PRR:AU A$0.04 AUD 0.00

PRR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PRR.
View Industry Companies
 

Industry Analysis

PRR

Industry Average

Valuation PRR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 33.7x
Price/Book 1.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 31.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PRIMA BIOMED LTD, please visit www.primabiomed.com.au. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.